Trifluoroacetic acid → 2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-10-(1-isopropylpiperidin-4-ylsulfinyl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine

Participants

Reaction Conditions

Reaction Steps

To an ice-cooled solution of 2-(2-isopropyl-5-methyl-2H-[1,2,4]triazol-3-yl)-9-(1-isopropylpiperidin-4-ylsulfanyl)-4,5-dihydro-6-oxa-1,3a-diazabenzo[e]azulene from Example 6 (146 mg, 0.313 mmol) in DCM (10 mL) was added TFA (72 μL, 0.939 mmol) followed by a solution of m-CPBA (59 mg, 0.344 mmol) in DCM (2 mL). The resulting mixture was stirred for 1 h at 0° C. then volatiles were removed under reduced pressure. The crude material was purified by column chromatography (C18, gradient 15-40% MeOH in 0.5% TFA/H2O) and then loaded onto an Isolute® SCX-2 cartridge. The cartridge was washed with MeOH and the product was eluted with 0.5M NH3 in MeOH affording 206 as a colorless foam (130 mg, 86%). LCMS: RT 2.47 min [M+H]+ 483.1. 1H NMR (DMSO, 400 MHz): δ 8.59 (1H, d, J=2.27 Hz), 7.93 (1H, s), 7.53 (1H, dd, J=8.53, 2.29 Hz), 7.25 (1H, d, J=8.53 Hz), 5.71-5.58 (1H, m), 4.62-4.50 (4H, m), 2.8-2.75 (2H, m), 2.74-2.58 (2H, m), 2.26 (3H, s), 2.13-2.03 (2H, m), 1.78 (1H, bd, J=12.31 Hz), 1.61 (1H, bd, J=12.24 Hz), 1.50-1.33 (7H, m), 0.90 (6H, d, J=6.54 Hz)

Provenance & Evidence